◆英語タイトル:Lidds AB (LIDDS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7952
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Lidds AB (Lidds) is a developer of pharmaceutical products for the treatment of cancer and other diseases. The company offers Liproca Depot, an injectable product used for the treatment of prostate cancer. Its Liproca is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid that is prepared as a paste prior to injection. Lidds’ develops efficient drugs for cancer and other diseases based on its unique proprietary NanoZolid technology. The company’s NanoZolid technology is combined with antiandrogens, cytostatics and immune-active molecules for the treatment of various types of cancer tumours, such as prostate and lung cancer.. Lidds is headquartered in Uppsala, Sweden.
Lidds AB (LIDDS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lidds AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lidds AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lidds AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lidds AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lidds AB, Medical Devices Deals, 2012 to YTD 2018 9
Lidds AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lidds AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
LIDDS Enters into Research Agreement with Karolinska Institute 11
LIDDS Enters into Research Agreement with Ferring Pharma 12
Lidds Enters into Research Agreement with Uppsala University 13
Licensing Agreements 14
Jiangxi Puheng Pharma to Enter into Licensing Agreement with LIDDS 14
Belina Pharma to Enter into Option for Exclusive License Agreement with Lidds 15
Equity Offering 16
LIDDS to Raise USD2.5 Million in Private Placement of Shares 16
Lidds to Raise USD1.7 Million in Private Placement of Shares 17
LIDDS Raises USD2 Million in Rights Offering of Shares 18
Lidds to Raise USD0.5 Million in Private Placement of Shares 19
Lidds to Raise USD3 Million in Rights Offering of Shares 20
Lidds to Raise USD1.3 Million in Private Placement of Shares 21
LIDDS Raises USD1.6 Million in Rights Offering of Shares 22
Lidds AB – Key Competitors 23
Lidds AB – Key Employees 24
Lidds AB – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Government and Public Interest 26
Jun 25, 2018: LIDDS’ NanoZolid technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technology 26
Product News 27
Nov 24, 2017: LIDDS initiates multiple immuno-oncology feasibility studies 27
07/20/2017: Recipharm and LIDDS establish industrial manufacturing capabilities for a novel prostate cancer product 28
May 16, 2018: LIDDS verifies NanoZolid for controlled release of cancer drugs 29
May 15, 2018: LIDDS broadens the scope of its technology platform by verifying NanoZolid as subcutaneous depot for systemic delivery 30
Mar 15, 2018: NanoZolid with cutting edge STING agonist becomes a key project for LIDDS in immuno-oncology field 31
Clinical Trials 32
Feb 08, 2018: Liproca Depot effects on prostate cancer to be presented at the Paris Symposium for Magnetic Resonance in Medicine 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33
List of Tables
Lidds AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lidds AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lidds AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lidds AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lidds AB, Deals By Therapy Area, 2012 to YTD 2018 8
Lidds AB, Medical Devices Deals, 2012 to YTD 2018 9
Lidds AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
LIDDS Enters into Research Agreement with Karolinska Institute 11
LIDDS Enters into Research Agreement with Ferring Pharma 12
Lidds Enters into Research Agreement with Uppsala University 13
Jiangxi Puheng Pharma to Enter into Licensing Agreement with LIDDS 14
Belina Pharma to Enter into Option for Exclusive License Agreement with Lidds 15
LIDDS to Raise USD2.5 Million in Private Placement of Shares 16
Lidds to Raise USD1.7 Million in Private Placement of Shares 17
LIDDS Raises USD2 Million in Rights Offering of Shares 18
Lidds to Raise USD0.5 Million in Private Placement of Shares 19
Lidds to Raise USD3 Million in Rights Offering of Shares 20
Lidds to Raise USD1.3 Million in Private Placement of Shares 21
LIDDS Raises USD1.6 Million in Rights Offering of Shares 22
Lidds AB, Key Competitors 23
Lidds AB, Key Employees 24
List of Figures
Lidds AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lidds AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lidds AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lidds AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lidds AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lidds AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lidds AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lidds AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lidds AB, Medical Devices Deals, 2012 to YTD 2018 9